{"id":"217308c4-6cc1-57dc-9a08-666a8a901a4d","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-polymorph-decides-brain-levels","predicate":"increases","statement":"Polymorph B and polymorph C both increased survival in a GL261 glioma model with B exhibiting greater toxicity, polymorph A showed no benefit, B and C both reached brain concentrations exceeding the GL261 half-maximal inhibitory concentration 29-fold, polymorph C demonstrated a 24-hour brain-to-plasma area-under-curve ratio of 0.82 while B showed higher plasma exposure and a lower ratio, polymorph A presented markedly lower levels in both plasma and brain, and combination with elacridar significantly improved the efficacy of polymorph C in glioma and medulloblastoma models.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"92a1ca80-4056-5f20-ba24-b1f4e3982607","mechanism_event_label":"The same crystal form that works against worms is the one that gets into the brain; the inert form stays out of the blood entirely.","subject":{"id":"1f996273-d9f1-5c5c-acd8-ec168cfebd64","slug":"mebendazole-polymorph-c","display_name":"Mebendazole polymorph C","entity_type_key":"chemical_species"},"object":{"id":"7252a778-c344-5df7-9593-bf4de85a30c3","slug":"brain-to-plasma-ratio","display_name":"Brain to plasma exposure ratio","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"92a1ca80-4056-5f20-ba24-b1f4e3982607","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-polymorph-decides-brain-levels-event","event_type":"biochemical_relationship","label":"The same crystal form that works against worms is the one that gets into the brain; the inert form stays out of the blood entirely.","description":"Polymorph B and polymorph C both increased survival in a GL261 glioma model with B exhibiting greater toxicity, polymorph A showed no benefit, B and C both reached brain concentrations exceeding the GL261 half-maximal inhibitory concentration 29-fold, polymorph C demonstrated a 24-hour brain-to-plasma area-under-curve ratio of 0.82 while B showed higher plasma exposure and a lower ratio, polymorph A presented markedly lower levels in both plasma and brain, and combination with elacridar significantly improved the efficacy of polymorph C in glioma and medulloblastoma models.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"c035837e-301e-5643-8242-c1483f7f423d","slug":"mebendazole-polymorph-a","display_name":"Mebendazole polymorph A","entity_type_key":"chemical_species"},"role":"inactive_form","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"083bffe6-7974-58f0-ad9f-9c1cd7a5193f","slug":"mebendazole-polymorph-b","display_name":"Mebendazole polymorph B","entity_type_key":"chemical_species"},"role":"toxic_form","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"198265f9-f579-5fb7-83e0-e244378305cd","slug":"elacridar","display_name":"Elacridar, an ABCB1 and ABCG2 inhibitor","entity_type_key":"chemical_species"},"role":"enhancing_agent","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"c6139b52-4140-5622-9e33-1f6c6385265d","slug":"abcb1","display_name":"Human P-glycoprotein / ABCB1 / MDR1","entity_type_key":"protein"},"role":"efflux_transporter","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"a52e10c2-fd56-564b-8c05-27e9fce27cd6","slug":"abcg2","display_name":"Human ABCG2 / breast cancer resistance protein","entity_type_key":"protein"},"role":"efflux_transporter","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"ace31cb7-2519-519c-aa9b-5ebdd5bf437e","slug":"orthotopic-glioma-survival","display_name":"Survival of mice bearing orthotopic glioma","entity_type_key":"cellular_process"},"role":"measured_endpoint","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""},{"entity":{"id":"1f996273-d9f1-5c5c-acd8-ec168cfebd64","slug":"mebendazole-polymorph-c","display_name":"Mebendazole polymorph C","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":6,"notes":""},{"entity":{"id":"7252a778-c344-5df7-9593-bf4de85a30c3","slug":"brain-to-plasma-ratio","display_name":"Brain to plasma exposure ratio","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":7,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/mebendazole-research/25862759.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"7545a89b4d17461bbe2d8ac8c7f3093b6ae0ce2f20307ab57b524d91f4f827c3\", \"start_char\": 0, \"end_char\": 1682, \"text_sha256\": \"7545a89b4d17461bbe2d8ac8c7f3093b6ae0ce2f20307ab57b524d91f4f827c3\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Polymorph content of marketed and custom tablets measured by infrared spectroscopy, then tested in orthotopic mouse glioma and medulloblastoma models with LC/MS pharmacokinetics","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Polymorphs A, B and C, alone and with the transporter inhibitor elacridar","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Carries the polymorph distinction across from the anthelmintic use into the oncology use and finds it decides brain exposure. Mouse models, and elacridar is an experimental tool rather than a co-therapy.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.","comparator":null,"unit":null,"notes":"","entity":{"slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Mouse","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The same crystal form that works against worms is the one that gets into the brain; the inert form stays out of the blood entirely.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[mbz-p25862759] Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model. (2015). https://pubmed.ncbi.nlm.nih.gov/25862759/ DOI: 10.1158/1078-0432.ccr-14-2681","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Brain and plasma","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"9db23e71-bc15-546a-b86c-94ffa776186a","evidence_kind":"source_excerpt","locator":"Lines 524-535","start_line":524,"end_line":535,"excerpt":"### mbz-polymorph-decides-brain-levels\nPolymorph B and polymorph C both increased survival in a GL261 glioma model with B exhibiting greater toxicity, polymorph A showed no benefit, B and C both reached brain concentrations exceeding the GL261 half-maximal inhibitory concentration 29-fold, polymorph C demonstrated a 24-hour brain-to-plasma area-under-curve ratio of 0.82 while B showed higher plasma exposure and a lower ratio, polymorph A presented markedly lower levels in both plasma and brain, and combination with elacridar significantly improved the efficacy of polymorph C in glioma and medulloblastoma models.\nCondition category: biomarker_context\nnutrient_topic: Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.\nplain_language: The same crystal form that works against worms is the one that gets into the brain; the inert form stays out of the blood entirely.\norganism: Mouse\ntissue_or_cell_type: Brain and plasma\nexperimental_model: Polymorph content of marketed and custom tablets measured by infrared spectroscopy, then tested in orthotopic mouse glioma and medulloblastoma models with LC/MS pharmacokinetics\nlimitations: Carries the polymorph distinction across from the anthelmintic use into the oncology use and finds it decides brain exposure. Mouse models, and elacridar is an experimental tool rather than a co-therapy.\nexposure: Polymorphs A, B and C, alone and with the transporter inhibitor elacridar\nevidence_span: {\"source_cache\": \"artifacts/mebendazole-research/25862759.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"7545a89b4d17461bbe2d8ac8c7f3093b6ae0ce2f20307ab57b524d91f4f827c3\", \"start_char\": 0, \"end_char\": 1682, \"text_sha256\": \"7545a89b4d17461bbe2d8ac8c7f3093b6ae0ce2f20307ab57b524d91f4f827c3\"}\n[mbz-p25862759] Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model. (2015). https://pubmed.ncbi.nlm.nih.gov/25862759/ DOI: 10.1158/1078-0432.ccr-14-2681","model_system":"Polymorph content of marketed and custom tablets measured by infrared spectroscopy, then tested in orthotopic mouse glioma and medulloblastoma models with LC/MS pharmacokinetics","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [mbz-p25862759] Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model. (2015). https://pubmed.ncbi.nlm.nih.gov/25862759/ DOI: 10.1158/1078-0432.ccr-14-2681","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"06104773-03d0-5e5c-b9da-eb484e7be657","stable_key":"import-f2ec2007-88ff-5a96-a73b-8b5085e9cea9","title":"Mebendazole: the tubulin it binds, why that is selective, the crystal form that decides whether any of it works, and the off-target that became an oncology programme (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"58b652636677e5033fd1dd555744485fcef18f21a97dcf68723fe072b656f413","revision_id":"a2cd9c22-0549-52ca-a653-8a0c2362ec85","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}